retatrutide clinical trial data Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA retatrutide clinical trial weight loss

Based on findings from the FLOW trial, recent guidelines have elevated GLP-1 receptor agonists to the same level of recommendation as SGLT2 inhibitors for people with CKD [84]

These are benefits that insulin and the vast majority of oral hypoglycemic agents do not have

The strength of the TRIUMPH-1 data 28.3% weight loss at 80 weeks, 45.3% achieving bariatric-surgery-level outcomes gives Eli Lilly a compelling submission package

However, federal law gives states the option whether to cover drugs used for weight loss

The glucagon component may also contribute to reduced hepatic lipid accumulation, which improves hepatic insulin sensitivity over time

Safe use requires medical supervision, gradual dose titration, and monitoring of metabolic markers such as glucose, digestion response, and weight trends